[
    [
        {
            "time": "2021-08-29",
            "original_text": "华东医药：公司全球独家胶原蛋白刺激剂长效微球Ellansé®伊妍仕®已于8月29日正式登陆中国大陆市场",
            "features": {
                "keywords": [
                    "华东医药",
                    "Ellansé",
                    "伊妍仕",
                    "医美",
                    "胶原蛋白刺激剂"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：公司全球独家胶原蛋白刺激剂长效微球Ellansé®伊妍仕®已于8月29日正式登陆中国大陆市场",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        },
        {
            "time": "2021-Q3",
            "original_text": "华西证券维持华东医药增持评级：Q3业绩环比实现增长，医药创新和医美业务布局稳步推进",
            "features": {
                "keywords": [
                    "华西证券",
                    "华东医药",
                    "Q3业绩",
                    "医美业务",
                    "医药创新"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华西证券维持华东医药增持评级：Q3业绩环比实现增长，医药创新和医美业务布局稳步推进",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-H1",
            "original_text": "华东医药：采用OXIFREE专利技术和工艺的新型高端含利多卡因玻尿酸填充MaiLi®系列产品已于2021年上半年在欧洲市场上市",
            "features": {
                "keywords": [
                    "华东医药",
                    "MaiLi",
                    "玻尿酸",
                    "欧洲市场",
                    "上市"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "华东医药：采用OXIFREE专利技术和工艺的新型高端含利多卡因玻尿酸填充MaiLi®系列产品已于2021年上半年在欧洲市场上市",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 4,
                "Headline_Structure": 7,
                "Source_Recency": 3
            }
        },
        {
            "time": "2021-Q1-Q3",
            "original_text": "安信证券给予华东医药买入评级，2021Q1-Q3医美业务快速增长，医美管线潜力有望逐步释放",
            "features": {
                "keywords": [
                    "安信证券",
                    "华东医药",
                    "医美业务",
                    "快速增长",
                    "管线潜力"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "安信证券给予华东医药买入评级，2021Q1-Q3医美业务快速增长，医美管线潜力有望逐步释放",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2021-全年",
            "original_text": "华东医药今年前三季增收不增利，医美业务有望超额完成全年目标",
            "features": {
                "keywords": [
                    "华东医药",
                    "前三季",
                    "增收不增利",
                    "医美业务",
                    "超额完成"
                ],
                "sentiment_score": 0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医美"
                ],
                "causal_factor": "true",
                "causal_impact": "mixed",
                "affected_by_time_series": "true",
                "ts_effect_direction": "mixed"
            },
            "scores": {
                "News_content": "华东医药今年前三季增收不增利，医美业务有望超额完成全年目标",
                "Correlation": 10,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 8,
                "Headline_Structure": 9,
                "Source_Recency": 8
            }
        },
        {
            "time": "2025-目标",
            "original_text": "华东医药：力争实现2025年创新业务板块占整体工业营收30%的阶段性目标",
            "features": {
                "keywords": [
                    "华东医药",
                    "创新业务",
                    "2025目标",
                    "工业营收"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药",
                    "创新"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "华东医药：力争实现2025年创新业务板块占整体工业营收30%的阶段性目标",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        }
    ]
]